Please login to the form below
PI3K
This page shows the latest PI3K news and features for those working in and with pharma, biotech and healthcare.
Chi-Med cues up two more regulatory filings in cancer
Following after its first three drugs are potential first-in-class selective Syk inhibitor HMPL-523, in phase 1 testing for non-Hodgkin’s lymphoma, and a PI3K delta inhibitor
Latest news
-
FDA clears Novartis’ new breast cancer drug Piqray
Blockbuster potential for PI3K drug. Novartis has gained FDA approval for its PI3K inhibitor Piqray for advanced breast cancer, bucking the trend for the drug class in solid tumour therapy. ... Rival Swiss pharma Roche was also developing a PI3K
-
Novartis sees five new $1bn-plus launches in next two years
among PI3K inhibitors.
-
Tecentriq combo shows promise in triple negative breast cancer
Ipatasertib is an oral, targeted drug that binds to all three isoforms of AKT, which blocks the PI3K/AKT signalling pathway and may prevent cancer cell growth and survival. ... The molecule is being studied in tumours that are frequently found to have
-
Novartis claims a rare win at ESMO for PI3K inhibitor class
Novartis thinks could be down to its high specificity for the PI3K alpha receptor. ... Roche scrapped taselisib for breast cancer after reporting the SANDPIPER results at ASCO, but said it is still interested in pursuing the PI3K mechanism with other
-
A look ahead to key trial readouts at ESMO
In breast cancer, Novartis will be presenting its SOLAR-1 study of alpha-specific PI3K inhibitor alpelisib (BYL719) in HR+/HER2- advanced breast cancer with PIK3CA mutations, and Clovis Oncology’s
More from news
Approximately 1 fully matching, plus 32 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
development and commercialisation. 45. Infinity Pharmaceuticals/ Verastem. Duvelisib, oral inhibitor of PI3K‐delta and PI3K‐gamma for haematological cancers (p3).
-
Deal Watch table for September 2014
970. Infinity / AbbVie. Licence and collaboration. IPI-145 an oral PI3K-delta, gamma inhibitor in Phase III for chronic lymphocytic leukaemia .
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Curis looks to MedImmune and Takeda for new hires
These include CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
- Europe’s cancer community publishes new report on transforming patient care
- Assessing the value of interim analyses in clinical trials
- Piloting a route to the biosimilars opportunities in Europe
- Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
